Endocrine Therapies in Breast Cancer

Paperback | November 15, 2007

EditorAman U. Buzdar

not yet rated|write a review
Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to themanagement of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen.New and emerging indications for the aromatase inhibitors are providing clinicans (and patients) with alternative treatment options with differing side effect profiles.Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists fromthe MD Anderson Cancer Center, the book covers the range of endocrine therapies currently available to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes useful chapterson the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer. This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer.

Pricing and Purchase Info

$13.95

Ships within 1-3 weeks
Ships free on orders over $25

From the Publisher

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to themanagement of their disease. Tamoxifen has long been ...

Aman Buzdar is a Professor of Breast Medical Oncology, Oncology, University of Texas MD Anderson Cancer Center.

other books by Aman U. Buzdar

Oracle Database 12c Backup And Recovery Survival Guide
Oracle Database 12c Backup And Recovery Survival Guide

Paperback|Jul 28 2013

$78.48 online$88.95list price(save 11%)
The New Formal: Interiors By James Aman
The New Formal: Interiors By James Aman

Hardcover|Oct 18 2016

$71.37 online$79.00list price(save 9%)
The Fox Wish
The Fox Wish

Hardcover|Mar 14 2017

$21.35 online$23.99list price(save 11%)
see all books by Aman U. Buzdar
Format:PaperbackDimensions:128 pages, 7.09 × 3.94 × 0.24 inPublished:November 15, 2007Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0199218145

ISBN - 13:9780199218141

Look for similar items by category:

Customer Reviews of Endocrine Therapies in Breast Cancer

Reviews

Extra Content

Table of Contents

1. Dr W. Fraser Symmans and Dr Lajos Pusztai: Selection of patients for endocrine therapies2. Kellie L. Jones: Ovarian ablation3. Professor John F. Forbes: Antiestrogens4. Laura B. Michaud: Aromatase inhibitors in early and advanced disease5. Professor John FR Roberston, Mr Kwok-Leung Cheung and Mr Amit Agrawal: Fulvestrant - Metastatic disease6. Janet Espirito: Progestins and androgens7. Professor Aman U. Buzdar: Combined endocrine and chemotherapy8. Dr Rena V. Sellin: Hormonal replacement therapy in patients with prior history of breast cancer9. Professor Jack Cuzick: Prevention